基于纳米载体的新兴基因治疗：心血管疾病的一种有前景的治疗选择及心脏瓣膜病的一种新策略

Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.

作者信息

Yang Haoran, Li Junli, Song Chengxiang, Li Hongde, Luo Qiang, Chen Mao

机构信息

Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.

Department of Cardiology, West China Hospital, Sichuan University, No.37 Guoxue Street, Chengdu 610041, China.

出版信息

Int J Mol Sci. 2025 Feb 18;26(4):1743. doi: 10.3390/ijms26041743.

DOI:10.3390/ijms26041743

PMID:40004206

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11855571/

Abstract

Cardiovascular disease remains a leading cause of global mortality, with many unresolved issues in current clinical treatment strategies despite years of extensive research. Due to the great progress in nanotechnology and gene therapy in recent years, the emerging gene therapy based on nanocarriers has provided a promising therapeutic alternative for cardiovascular diseases. This review outlines the status of nanocarriers as vectors in gene therapy for cardiovascular diseases, including coronary heart disease, pulmonary hypertension, hypertension, and valvular heart disease. It discusses challenges and future prospects, aiming to support emerging clinical treatments. This review is the first to summarize gene therapy using nanocarriers for valvular heart disease, highlighting their potential in targeting challenging tissues.

摘要

心血管疾病仍然是全球死亡的主要原因，尽管经过多年广泛研究，目前的临床治疗策略仍存在许多未解决的问题。由于近年来纳米技术和基因治疗取得了巨大进展，基于纳米载体的新兴基因治疗为心血管疾病提供了一种有前景的治疗选择。本综述概述了纳米载体作为心血管疾病基因治疗载体的现状，包括冠心病、肺动脉高压、高血压和心脏瓣膜病。它讨论了挑战和未来前景，旨在支持新兴的临床治疗。本综述首次总结了使用纳米载体治疗心脏瓣膜病的基因治疗，强调了它们在靶向具有挑战性的组织方面的潜力。